GSK Unveils Detailed Phase 3 Data For Jemperli In Frontline Endometrial Cancer Patients

  • AnaptysBio Inc's ANAB partner GSK Plc GSK shared interim results from Part 1 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase 3 trial investigating Jemperli (dostarlimab) plus standard-of-care chemotherapy (carboplatin-paclitaxel) followed by dostarlimab alone for primary advanced or recurrent endometrial cancer.
  • In an interim analysis, Jemperli was shown to extend progression-free survival for both the subset and the overall trial population when added to chemotherapy.
  • Related: AnaptysBio / GSK-Partnered Immuno-Oncology Agent Meets Primary Goal In Lung Cancer Trial.
  • GSK reported that after 24 months, 36.1% of the 245 patients in the Jemperli plus chemotherapy arm were still alive and did not see their cancer progress, compared with 18.1% of the 249 patients who received placebo and chemotherapy. 
  • For patients whose tumors are considered mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H), the PFS rate for the Jemperli arm (with 53 patients) is 61.4% versus 18.1% for the placebo arm (65 patients).
  • 72% and 36% reduction in the risk of disease progression or death were observed in the dMMR/MSI-H and overall patient populations, respectively.
  • Regulatory submissions are planned for the first half of 2023.
  • Price Action: ANAB stock is down 0.91% at $21.70, and GSK shares are up 0.21% at $35.12 on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechLarge CapNewsPenny StocksHealth CareSmall CapGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!